Medicine Recommendations

For the management of sleep disturbance in patients with Alzheimer’s dementia

Alzheimer's Dementia (NICE TA217)

NICE TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

MHRA Drug Safety Update - Memantine pump device (Ebixa): risk of medication errors

Short term use in anxiety

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

ADHD in children, adolescents and adults

NICE guideline NG87: Attention deficit hyperactivity disorder: diagnosis and management

Nausea associated with Acute Migraine

MHRA Drug Safety Update - Metoclopramide: risk of neurological adverse effects

Nausea and vomiting

Opioid-induced nausea and vomiting

Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Status Epilepticus

MHRA Drug Safety Update - Buccal midazolam (Buccolam▼): new authorised medicine for paediatric use

Status Epilepticus

Breathlessness

Care in the last weeks or days of life - Breathlessness in the last days of life AND Agitation/terminal restlessness in the last days of life

Palliative care emergencies - Seizures AND Anixolytic following major blood loss

Depressive illness

Depressive illness, social phobia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Narcolepsy

MHRA Drug Safety Update - Modafinil: now restricted to narcolepsy

Pain

MHRA Drug Safety Update - Drugs and driving: blood concentration limits set for certain drugs

Breathlessness

Pain in the last weeks or days of life

Breathlessness in the last days of life

Pain

Severe pain and breathlessness in patients with symptoms due to a palliative (life limiting) illness

Complex pain syndrome

MHRA Drug Safety Alert - Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men

MHRA Drug Safety Alert - Mycophenolate mofetil: pure red cell aplasia

MHRA Drug Safety Alert - Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

Alcohol dependence (NICE TA325)

NICE TA325  Nalmefene for reducing alcohol consumption in people with alcohol dependence

Managing overweight and obesity (NICE TA494)

NICE TA494 - Naltrexone–bupropion for managing overweight and obesity

Pain: Anti-inflammatory